WuXi Biologics Included in Hang Seng ESG 50 Index
WuXi Biologics, a leading global CRDMO, has been included in the Hang Seng ESG 50 Index, effective September 9, 2024. It is the only pharmaceutical company selected this year. The index captures the performance of the top 50 ESG leaders with high market capitalization listed in Hong Kong.
In the 2024 HKQAA Sustainability Ratings, WuXi Biologics earned an A rating, ranking in the top 10% among industry peers in areas such as corporate governance, human rights, labor practices, environment, and community involvement.
The company has made significant progress in sustainable development, aligning with the UN Sustainable Development Goals. It is a signatory to the UN Global Compact and the Science Based Targets initiative. WuXi Biologics has also received recognition from major ESG rating agencies, including an AAA rating from MSCI ESG Ratings and a Platinum Medal from EcoVadis.
WuXi Biologics, un importante CRDMO globale, è stata inclusa nell'Hang Seng ESG 50 Index, con effetto dal 9 settembre 2024. È l'unica azienda farmaceutica selezionata quest'anno. L'indice riflette le prestazioni dei primi 50 leader ESG con alta capitalizzazione di mercato quotati a Hong Kong.
Nelle valutazioni di sostenibilità HKQAA 2024, WuXi Biologics ha ottenuto un rating A, posizionandosi nel 10% migliore tra i concorrenti del settore in aree come governance aziendale, diritti umani, pratiche lavorative, ambiente e coinvolgimento comunitario.
L'azienda ha compiuto progressi significativi nello sviluppo sostenibile, allineandosi con gli Obiettivi di Sviluppo Sostenibile delle Nazioni Unite. È firmataria del Global Compact delle Nazioni Unite e dell'iniziativa Science Based Targets. WuXi Biologics ha anche ricevuto riconoscimenti da importanti agenzie di valutazione ESG, inclusi un rating AAA dalle valutazioni MSCI ESG e una Medaglia Platino da EcoVadis.
WuXi Biologics, un CRDMO global líder, ha sido incluida en el índice Hang Seng ESG 50, con efecto desde el 9 de septiembre de 2024. Es la única empresa farmacéutica seleccionada este año. El índice capta el rendimiento de los 50 principales líderes ESG con alta capitalización de mercado que cotizan en Hong Kong.
En las calificaciones de sostenibilidad HKQAA 2024, WuXi Biologics obtuvo una calificación A, posicionándose en el 10% superior entre sus pares de la industria en áreas como gobernanza corporativa, derechos humanos, prácticas laborales, medio ambiente e involucramiento comunitario.
La empresa ha realizado avances significativos en desarrollo sostenible, alineándose con los Objetivos de Desarrollo Sostenible de la ONU. Es signataria del Pacto Global de la ONU y de la iniciativa Science Based Targets. WuXi Biologics también ha recibido reconocimientos de importantes agencias de calificación ESG, incluyendo una calificación AAA de MSCI ESG Ratings y una Medalla Platino de EcoVadis.
우시 생물학(WuXi Biologics), 세계적인 CRDMO의 선두주자로서 항셍 ESG 50 지수(Hang Seng ESG 50 Index)에 포함되었으며, 2024년 9월 9일부터 유효합니다. 올해 선택된 제약 회사는 유일합니다. 이 지수는 홍콩에 상장된 시가총액이 큰 상위 50개 ESG 리더의 성과를 반영합니다.
2024 HKQAA 지속 가능성 평가에서 우시 생물학은 A 등급을 받아 산업 동료 중 상위 10%에 랭크되었습니다. 기업 거버넌스, 인권, 노동 관행, 환경 및 지역 사회 참여와 같은 분야에서 우수성을 보여줍니다.
회사는 UN 지속 가능 개발 목표에 맞춰 지속 가능한 개발에서 상당한 진전을 이루었습니다. 우시는 UN 글로벌 컴팩트 및 과학 기반 목표 이니셔티브의 서명자입니다. 또한, 우시 생물학은 MSCI ESG Ratings로부터 AAA 등급과 EcoVadis로부터 플래티넘 메달을 수상하는 등 주요 ESG 평가 기관으로부터 인정을 받았습니다.
WuXi Biologics, un CRDMO mondial de premier plan, a été inclus dans l'indice Hang Seng ESG 50, avec effet au 9 septembre 2024. C'est la seule entreprise pharmaceutique sélectionnée cette année. L'indice reflète la performance des 50 principaux leaders ESG ayant une forte capitalisation boursière cotés à Hong Kong.
Dans les évaluations de durabilité HKQAA 2024, WuXi Biologics a obtenu une note A, se classant dans le top 10% parmi ses pairs de l'industrie dans des domaines tels que la gouvernance d'entreprise, les droits de l'homme, les pratiques de travail, l'environnement et l'engagement communautaire.
L'entreprise a réalisé des progrès significatifs en matière de développement durable, s'alignant sur les Objectifs de développement durable de l'ONU. Elle est signataire du Pacte mondial des Nations Unies et de l'initiative Science Based Targets. WuXi Biologics a également été reconnue par des agences de notation ESG majeures, notamment avec une note AAA des MSCI ESG Ratings et une médaille Platine d'EcoVadis.
WuXi Biologics, ein führender globaler CRDMO, wurde in den Hang Seng ESG 50 Index aufgenommen, der ab dem 9. September 2024 gültig ist. Es ist das einzige Pharmaunternehmen, das in diesem Jahr ausgewählt wurde. Der Index erfasst die Leistung der 50 besten ESG-Führer mit einer hohen Marktkapitalisierung, die an der Börse in Hongkong gelistet sind.
Im Jahr 2024 erhielt WuXi Biologics bei den HKQAA Nachhaltigkeitsbewertungen eine A-Bewertung und gehört damit zu den Top 10% seiner Branchenkollegen in Bereichen wie Unternehmensführung, Menschenrechte, Arbeitspraktiken, Umwelt und gesellschaftlichem Engagement.
Das Unternehmen hat erhebliche Fortschritte in der nachhaltigen Entwicklung erzielt und sich an den UN-Zielen für nachhaltige Entwicklung orientiert. Es ist Unterzeichner des UN Global Compact und der Science Based Targets Initiative. WuXi Biologics wurde zudem von führenden ESG-Bewertungsagenturen anerkannt, darunter eine AAA-Bewertung von MSCI ESG Ratings und eine Platinmedaille von EcoVadis.
- None.
- None.
Launched in 2020, the Hang Seng ESG 50 Index aims to capture the performance of Top 50 ESG leaders with relatively high market-capitalization listed in
In the newly-published 2024 HKQAA Sustainability Ratings results released in late August, WuXi Biologics earned a rating of A, with a Top
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very pleased to be included in Hang Seng ESG 50 Index, a recognition that underscores our ongoing commitment to enhancing our ESG capabilities. Moving forward, we will steadfastly follow our ESG strategy and further advance the company's sustainable development to deliver consistently strong performance for the common good of the global community."
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making significant progress in pursuing sustainable development and socially responsible policy initiatives. Demonstrating its commitment, the company is a signatory to the United Nations Global Compact, as well as the global Science Based Targets initiative (SBTi) commitment letter.
The company's efforts have been recognized by major ESG rating agencies. It was granted an "AAA" rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis; included in the DJSI World Index and Emerging Markets Index; named to the MSCI ESG Leaders Indexes; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; and named a Constituent of the FTSE4Good Index Series.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-included-in-hang-seng-esg-50-index-302255421.html
SOURCE WuXi Biologics
FAQ
When was WuXi Biologics (WXXWY) included in the Hang Seng ESG 50 Index?
What rating did WuXi Biologics (WXXWY) receive in the 2024 HKQAA Sustainability Ratings?
How did WuXi Biologics (WXXWY) perform compared to industry peers in the 2024 HKQAA Sustainability Ratings?
What global initiatives has WuXi Biologics (WXXWY) signed?
What MSCI ESG rating did WuXi Biologics (WXXWY) receive?
